Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04879329
Title A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

transitional cell carcinoma

urethra transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Disitamab vedotin

Disitamab vedotin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.